论文部分内容阅读
目的研究HD-MTX静脉化疗的脑脊液药代动力学,为临床用药提供实验依据。方法采用反相高效液相色谱法对30例肿瘤患者静脉滴入MTX(1．0-3．0／次)后的脑脊液和血浆中MTX浓度进行连续测定。结果滴注MTX后0、6、12、24和36 h的脑脊液浓度分别为(1．65±1．52)×10-6、(4．3±3．34)×10-7、(1．46±1．10)×10-7和(3． 19±4．38)×10-8moL／L,36h时已测不出MTX浓度,它的药-时曲线与血浆相类似。直线回归方程:Y=0．057 97+0．010 82x(r= 0．8357)。结论脑脊液中MTX代谢呈二室模型,与血药浓度正相关。
Objective To study the cerebrospinal fluid pharmacokinetics of HD-MTX intravenous chemotherapy and provide experimental evidence for clinical use. Methods The concentrations of MTX in cerebrospinal fluid (CSF) and plasma were determined continuously by reversed-phase high performance liquid chromatography (RP-HPLC) in 30 patients with tumor after intravenous infusion of MTX (1.0-3.0) Results The concentrations of CSF at 0, 6, 12, 24 and 36 h after MTX injection were (1.65 ± 1.52) × 10-6 and (4.3 ± 3.34) × 10-7, respectively .46 ± 1.10) × 10-7 and (3.19 ± 4.38) × 10-8moL / L, respectively. No MTX concentration was detected at 36h, and its drug-time curve was similar to that of plasma. Linear regression equation: Y = 0.057 97 + 0.010 82x (r = 0.8357). Conclusion MTX metabolism in cerebrospinal fluid showed a two-compartment model with a positive correlation with plasma concentration.